Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.52 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.51 |
| ▸ | ELANE | P08246 | 2/20 | 0.51 |
| ▸ | CTSV | O60911 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9431930 | 0.87 | L3MBTL1 (0.65) | FOLH1L3MBTL1KDM4EALDH1A1POLB | |
| SCHEMBL321453 | 0.87 | PARP1 (0.57) | FOLH1L3MBTL1KDM4EALDH1A1POLB | |
| SCHEMBL5583147 | 0.87 | MCL1 (0.63) | FOLH1L3MBTL1KDM4EALDH1A1POLB | |
| SCHEMBL10089235 | 0.86 | FOLH1 (0.69) | FOLH1L3MBTL1KDM4EALDH1A1POLB | |
| SCHEMBL1649243 | 0.85 | FOLH1 (0.68) | FOLH1L3MBTL1KDM4EALDH1A1POLB | |
| SCHEMBL384896 | 0.85 | FOLH1 (0.68) | FOLH1L3MBTL1KDM4EALDH1A1POLB | |
| SCHEMBL344833 | 0.85 | FOLH1 (0.68) | FOLH1L3MBTL1KDM4EALDH1A1POLB | |
| SCHEMBL1647498 | 0.84 | FOLH1 (0.63) | FOLH1L3MBTL1KDM4EALDH1A1POLB | |
| SCHEMBL1647381 | 0.84 | FOLH1 (0.67) | FOLH1L3MBTL1KDM4EALDH1A1POLB | |
| SCHEMBL1646699 | 0.84 | FOLH1 (0.67) | FOLH1L3MBTL1KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198886-B2 | Use of 2,5-dihydroxybenzene for the treatment of ocular diseases | CUEVAS SÁNCHEZ PEDRO (ES) | 2015-12-01 | — | — | US | claimed |
| US-20140206654-A1 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF HEMATOLOGICAL DYSCRASIAS AND CANCER OF AN ORGAN | ACTION MEDICINES, S.L. (ES) | 2014-07-24 | — | — | US | claimed |
| EP-2061453-B1 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES SL (ES) | 2013-03-13 | — | — | EP | claimed |
| US-20120015912-A1 | USE OF 2,5-DIHYDROXYBENZENE FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES (ES) | 2012-01-19 | — | — | US | claimed |
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES (ES) | 2011-10-20 | — | — | US | claimed |
| EP-2061453-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | Action Medicines, S.L. (ES) | 2009-05-27 | — | — | EP | claimed |
| EP-2056805-A1 | USE OF 2, 5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTIVE DISEASES | Action Medicines, S.L. (ES) | 2009-05-13 | — | — | EP | claimed |
| EP-2056804-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF OCULAR DISEASES | Action Medicines, S.L. (ES) | 2009-05-13 | — | — | EP | claimed |
| EP-2054051-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | Investread Europe, S.L. (ES) | 2009-05-06 | — | — | EP | claimed |
| US-20080125485-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid; skin disorders like skin wrinkles, actinic keratosis, skin pigmentation and hyperpigmentation, hirsutism and hypertricosis, obesity due to adipogenesis | ACTION MEDICINES (ES) | 2008-05-29 | — | — | US | claimed |
| US-20080125486-A1 | sultosilic acid, 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid, used for improving the efficacy of chemotherapy, radiotherapy and/or cancer immunotherapy | ACTION MEDICINES (ES) | 2008-05-29 | — | — | US | claimed |
| US-20080114063-A1 | Use of 2,5-Dihydroxybenzene Derivatives for the Treatment of Tissue Reactive Diseases | ACTION MEDICINES (ES) | 2008-05-15 | — | — | US | claimed |
| WO-2008020039-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020031-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ANGIOGENIC DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020037-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING OBESITY, HIRSUTISM, HYPERTRICOSIS AND VIRAL WARTS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020034-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF HEMANGIOMAS OR HEMANGIOBLASTOMAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020042-A1 | USE OF 2, 5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTIVE DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020025-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020032-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2025242903-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ONCO3R THERAPEUTICS BV (BE) | 2025-11-27 | — | — | WO | disclosed |
| CN-117794526-A | Compositions and methods for antioxidants and anti-inflammatory therapeutics | 阿万蒂生物科学股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20190192474-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | AmDerma Pharmaceuticals, LLC | 2019-06-27 | — | — | US | disclosed |
| US-10278940-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-20170065547-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | ACTION MEDICINES, S.L. (ES) | 2017-03-09 | — | — | US | disclosed |
| US-9511044-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9248114-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ | ACTION MEDICINES, S.L. (ES) | 2016-02-02 | — | — | US | disclosed |
| US-9198886-B2 | Use of 2,5-dihydroxybenzene for the treatment of ocular diseases | CUEVAS SÁNCHEZ PEDRO (ES) | 2015-12-01 | — | — | US | disclosed |
| US-9060966-B2 | Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain | CUEVAS SÁNCHEZ PEDRO (ES) | 2015-06-23 | — | — | US | disclosed |
| US-9018195-B2 | Use of 2,5-dihydroxybenzene sulfonic acid compounds for treating skin photoaging | AmDerma Pharmaceuticals, LLC (US) | 2015-04-28 | — | — | US | disclosed |
| US-8889737-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140328823-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | AmDerma Pharmaceuticals, LLC | 2014-11-06 | — | — | US | disclosed |
| EP-2483254-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2014-08-13 | — | — | EP | disclosed |
| US-20140206654-A1 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF HEMATOLOGICAL DYSCRASIAS AND CANCER OF AN ORGAN | ACTION MEDICINES, S.L. (ES) | 2014-07-24 | — | — | US | disclosed |
| US-8778939-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8541467-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ | ACTION MEDICINES, S.L. (ES) | 2013-09-24 | — | — | US | disclosed |
| US-20130202580-A1 | Use Of 2,5-Dihydroxybenzene Derivatives For Treating Actinic Keratosis | AmDerma Pharmaceuticals, LLC (US) | 2013-08-08 | — | — | US | disclosed |
| US-8436045-B2 | Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis | AmDerma Pharmaceuticals, LLC (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2061453-B1 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES SL (ES) | 2013-03-13 | — | — | EP | disclosed |
| EP-2483254-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184553-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-07-19 | — | — | US | disclosed |
| US-20120087904-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | AmDerma Pharmaceuticals, LLC (US) | 2012-04-12 | — | — | US | disclosed |
| US-8101660-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-20120015912-A1 | USE OF 2,5-DIHYDROXYBENZENE FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES (ES) | 2012-01-19 | — | — | US | disclosed |
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES (ES) | 2011-10-20 | — | — | US | disclosed |
| US-20110152222-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | SANCHEZ PEDRO CUEVAS | 2011-06-23 | — | — | US | disclosed |
| WO-2011038572-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-04-07 | — | — | WO | disclosed |
| EP-2061453-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | Action Medicines, S.L. (ES) | 2009-05-27 | — | — | EP | disclosed |
| EP-2056805-A1 | USE OF 2, 5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTIVE DISEASES | Action Medicines, S.L. (ES) | 2009-05-13 | — | — | EP | disclosed |
| EP-2056804-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF OCULAR DISEASES | Action Medicines, S.L. (ES) | 2009-05-13 | — | — | EP | disclosed |
| EP-2054051-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | Investread Europe, S.L. (ES) | 2009-05-06 | — | — | EP | disclosed |
| EP-2054045-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | Action Medicines, S.L. (ES) | 2009-05-06 | — | — | EP | disclosed |
| US-20080125485-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid; skin disorders like skin wrinkles, actinic keratosis, skin pigmentation and hyperpigmentation, hirsutism and hypertricosis, obesity due to adipogenesis | ACTION MEDICINES (ES) | 2008-05-29 | — | — | US | disclosed |
| US-20080125486-A1 | sultosilic acid, 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid, used for improving the efficacy of chemotherapy, radiotherapy and/or cancer immunotherapy | ACTION MEDICINES (ES) | 2008-05-29 | — | — | US | disclosed |
| US-20080114060-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid, or sultosilic acid for example; combination therapy with other drugs or photodynamic therapy | ACTION MEDICINES (ES) | 2008-05-15 | — | — | US | disclosed |
| US-20080114063-A1 | Use of 2,5-Dihydroxybenzene Derivatives for the Treatment of Tissue Reactive Diseases | ACTION MEDICINES (ES) | 2008-05-15 | — | — | US | disclosed |
| WO-2008020039-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020027-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF SKIN CANCER | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020031-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ANGIOGENIC DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020037-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING OBESITY, HIRSUTISM, HYPERTRICOSIS AND VIRAL WARTS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020040-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF FIBROSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020034-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF HEMANGIOMAS OR HEMANGIOBLASTOMAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020033-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020042-A1 | USE OF 2, 5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTIVE DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020032-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020025-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125485-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid; skin disorders like skin wrinkles, actinic keratosis, skin pigmentation and hyperpigmentation, hirsutism and hypertricosis, obesity due to adipogenesis | ARSA, CYP8B1, EBP | FOLH1 2945/4885L3MBTL1 1572/4885KDM4E 1639/4885 |
| US-20080125486-A1 | sultosilic acid, 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid, used for improving the efficacy of chemotherapy, radiotherapy and/or cancer immunotherapy | STS, MPST, TST | FOLH1 2122/4885L3MBTL1 1107/4885KDM4E 1472/4885 |
| US-20140328823-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | FOLH1 1079/4885L3MBTL1 2095/4885KDM4E 540/4885 |
| US-20120087904-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | FOLH1 1079/4885L3MBTL1 2095/4885KDM4E 540/4885 |
| US-10278940-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | CYP8B1, CYP26B1, CYP24A1 | FOLH1 1079/4885L3MBTL1 2095/4885KDM4E 540/4885 |
| US-20130202580-A1 | Use Of 2,5-Dihydroxybenzene Derivatives For Treating Actinic Keratosis | CYP8B1, DERA, KRT18 | FOLH1 1186/4885L3MBTL1 3247/4885KDM4E 1371/4885 |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | FOLH1 1682/4885L3MBTL1 4366/4885KDM4E 3106/4885 |
| US-20120184553-A1 | NOVEL COMPOUNDS | LRRK2, PARK7, PINK1 | FOLH1 4250/4885L3MBTL1 1685/4885KDM4E 3000/4885 |
| US-20080114063-A1 | Use of 2,5-Dihydroxybenzene Derivatives for the Treatment of Tissue Reactive Diseases | CYP11B1, CYP11B2, MYLK | FOLH1 1263/4885L3MBTL1 3528/4885KDM4E 3075/4885 |
| US-20170065547-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | FOLH1 1079/4885L3MBTL1 2095/4885KDM4E 540/4885 |
| US-20120015912-A1 | USE OF 2,5-DIHYDROXYBENZENE FOR THE TREATMENT OF OCULAR DISEASES | ALDH1A2, CRYAB, HSD17B14 | FOLH1 2602/4885L3MBTL1 4541/4885KDM4E 1092/4885 |
| US-20190192474-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | FOLH1 1079/4885L3MBTL1 2095/4885KDM4E 540/4885 |
| US-20080114060-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid, or sultosilic acid for example; combination therapy with other drugs or photodynamic therapy | ALAD, ARSA, STS | FOLH1 1671/4885L3MBTL1 1695/4885KDM4E 3500/4885 |
| US-20140206654-A1 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF HEMATOLOGICAL DYSCRASIAS AND CANCER OF AN ORGAN | HMBS, HCLS1, CYP2S1 | FOLH1 1221/4885L3MBTL1 1009/4885KDM4E 821/4885 |
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | CYP8B1, DERA, KRT18 | FOLH1 1186/4885L3MBTL1 3247/4885KDM4E 1371/4885 |
| US-20110152222-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | CYP8B1, CYP26B1, UGT2B7 | FOLH1 1846/4885L3MBTL1 3750/4885KDM4E 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.